Company: ADPT
Filing Date: 2025-03-03
Form Type: 10-K
Source: 0000950170-25-030913
Chunk: 209

Company: Adaptive Biotechnologies Corp
Filing Date: 2025-03-03
Form: 10-K
Item: Item 1B
Chunk 209
---
) of the Securities Exchange Act of 1934, the registrant has duly caused this Annual Report on Form 10-K to be signed on its behalf by the undersigned, thereunto duly authorized, in the city of Seattle, State of Washington, on March 3, 2025.

    Adaptive Biotechnologies Corporation  

    By:    
     
    /s/ Chad Robins

    Chad RobinsChief Executive Officer

POWER OF ATTORNEY 

KNOW ALL PERSONS BY THESE PRESENTS, that each person whose signature appears below constitutes and appoints Chad Robins, his attorney-in-fact, with the power of substitution, for him in any and all capacities, to sign any amendments to this Annual Report on Form 10-K, and to file the same, with exhibits thereto and other documents in connection therewith, with the SEC, hereby ratifying and confirming all that said attorney-in-fact, or his substitute or substitutes, may do or cause to be done by virtue hereof.

Pursuant to the requirements of the Securities Exchange Act of 1934, this Annual Report on Form 10-K has been signed below by the following persons on behalf of the Registrant and in the capacities and on the dates indicated.

    Signature
     
    Title
     
    Date

    /s/ Chad RobinsChad Robins
     
    Chief Executive Officer and Director(Principal Executive Officer)
     
    March 3, 2025

    /s/ Kyle PiskelKyle Piskel
     
    Chief Financial Officer(Principal Financial Officer and Principal Accounting Officer)
     
    March 3, 2025

    /s/ Michelle GriffinMichelle Griffin
     
    Director 
     
    March 3, 2025

    /s/ Robert HershbergRobert Hershberg, PhD, MD
     
    Director 
     
    March 3, 2025

    /s/ Peter NeupertPeter Neupert
     
    Director 
     
    March 3, 2025

    /s/ Katey OwenKatey Owen, PhD
     
    Director 
     
    March 3, 2025

    /s/ Michael Pellini
     
    Director
     
    March 3, 2025

    Michael Pellini, MD

128